Voyager Therapeutics, Inc. (VYGR) AI Dilution Summary

Estimated cash was $116,338,000 as of 2026-06-30, the last balance-sheet date, against estimated monthly burn of $8,614,000. The company is funding itself through an at-the-market program with TD Securities (USA) LLC (TD Cowen), authorised to $100,000,000. Under it, 1,358,566 shares were sold since the program began through 2026-06-30, and sales after 2026-06-30 are not yet reported.